 |
|
|
| |
Ribavirin Management in HCV Genotype 4 Patients Receiving
Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in the Phase 3 AGATE-I Study
|
| |
| |
Reported by Jules Levin
EASL/AASLD - New Perspectives in Hepatitis C Virus Infection-The Roadmap for Cure, 23-24 September 2016, Paris, France
Christophe Hezode1, Tarek Hassanein2, Yves Horsmans3, Hermann Laferl4, Jose Luis Calleja5, Antonio Olveira6, Christophe Moreno7,
George Papatheodoridis8, Magdy Elkhashab9, Marisol Martinez10, Yao Yu10, Rebecca Redman10, Roula Qaqish10, Niloufar Mobashery10, Tarik Asselah11
1Hôpital Henri Mondor, AP-HP, Universite Paris-Est, Inserm, Creteil, France; 2Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States; 3Cliniques
Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium; 4Kaiser Franz Josef Hospital, 4th Medical Department with Infectious Diseases and Tropical Medicine, Vienna, Austria; 5Liver Unit. Hospital
Universitario Puerta de Hierro, Universidad Autonoma de Madrid, CIBERehd, Madrid, Spain; 6Liver Unit. Hospital Universitario, La Paz, CIBERehd, Madrid, Spain; 7CUB Hôpital Erasme, Universite Libre de Bruxelles,
Brussels, Belgium; 8Academic Department of Gastroenterology, Medical School of Nati onal and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; 9Toronto Liver Centre, Toronto, Ontario,
Canada; 10AbbVie Inc., North Chicago, Illinois, United States; 11Centre de Recherche sur l'Infl ammati on (CRI), Inserm UMR, Universite Paris Diderot, Service d'Hepatologie, AP-HP Hôpital Beaujon, Clichy, France
|
| |
|
|
|
|
|
